FDA Investigator Kelli F Dobilas

Kelli F Dobilas has conducted inspections on 111 sites in 2 countries as of 26 Mar 2019. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
111
Last Inspection Date:
26 Mar 2019
Investigator Role:
FDA Investigator
Redica ID:
100009366
Countries of Inspections:
Canada, United States of America
FDA Investigators that have inspected at least one site in common with Kelli F Dobilas:
Addam S Reynolds, Adetutu M Gidado, Albert M Brindle, Alberto A Viciedo, Ali A Patino, Alice S Tsao, Allen Lou, Amy A Johnson, Amy L Singer, Amy M Codella, Amy M Cramer, Ana S Cabrera, Andrew O Ejiofor, Anissa M Vargas, Ankur C Patel, Ann Marie Montemurro, Annemarie B Randow, Annemarie Bodnar, Annet R Rajan, Anthony J Donato, Anthony M Criscuolo, Jr, Anthony N Onianwa, Antoinette L Ravelli, Arsen Karapetyan, Atul J Agrawal, Azza Talaat, Barbara J Maulfair, Barbara Jwilimczyk Macri, Barbara L Rellahan, PhD, Bei Yu, Brandy N Lepage, Byungja E Marciante, Cara M Minelli, Cary Greene, CDR Thomas R Berry, PPh, Charles J Chacko, Charles M Edwards, Charlotte P Chang, Christina N Maurino, Christina P Burkhart, Christine M Cerenzio, Christopher J Adams, Constantin Y Philopoulos, Craig W Swanson, Cynthia F Kleppinger, MD, Daniel J Grabicki, Daniel T Lee, David H Smith, Dawn L Wydner, Deborah B Goffman, Deborah B Nixon, Demitria J Xiradakis, Denise M Visco, Investigator, Dhaval H Patel, Dolores Harper, Donald L Lech, Doreen P Canetti, Doreen P Gubbay, Dorothy J Denes, Douglas C Kovacs, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Edmund F Mrak, Jr, Edward O'shaughnessy, Elaine E Gilfillan, Emest F Bizjak, Emily A Walters, Emmanuel Jramos Maldonado, Eric J Cunningham, Eric Rothschild, Erin D Mccaffery, Esteban Beltran, Eufemia G Gonzalez, Frank J Marciniak, Frederick F Razzaghi, George M Ibrahim, George Pyramides, Gianine E Delade, Gianine E Tompkins, Gobiga Vanniyasingam, Guerlain Ulysse, Haitao Li, Helen B Ricalde, Helen Verdel, Ivan E Reyes, Jacqueline Mdiaz Albertini, Jacqueline S Warner, James A Liubicich, James E Frye, James R Birkenstamm, Janet A Rajan, Jawaid Hamid, Jean M Kelahan, Jean M Mulinde, MD, Jeffrey J Ebersole, Jennifer A Bazergui, Jennifer L Custodio, Jennifer Macmillan, Jessica M Monteiro, Jessica S Estriplet, Jill M Sooter, Jill Mielziner, Jo Annc Declement, Jogy George, Jonee J Mearns, Jose M Cayuela, Joseph F Mcginnis, RPh, Josh Renzo N Ramilo, Joy Rkozlowski Klena, Juanita P Versace, Judith A Paterson, Justin A Boyd, Justine Tomasso, Karen A Spencer, Karen E D'orazio, Karishma G Gopaul, Keith A Schwartz, Keith M Reilly, Kelli F Regenye, Kelli Regente, Kelly Doremus, Kelly I Anderson, Kelly L Anderson, Kevin Obrien, Kevin P Foley, Kinh Q Mac, Kish Bolden, Ko U Min, Kris K Moore, Krishnaiah Yellela, Kristen E Rescigno, Kristy A Zielny, Laishan L Lam, Larry Johnson, Lata C Mathew, PhD, Lauren L Vajo, Lawrence R Johnson, Li Li, Liatte Kreuger, PharmD, Lisa B Hall, Lisa Harlan, Lisa Mathew, Loretta Nemchik, Luis A Dasta, Marcellinus D Dordunoo, Marea K Harmon, Margaret M Sands, Maria Estrella, Maria Manzoni, PhD, Marjorie D Schultz, Matthew A Spataro, Matthew W Kyle, Melba Trivera Clavell, Melissa A Freeman, Melissa B Libby, Melissa T Roy, Meredith L Sheridan, Merril E Racke, Meyer J Slobotsky, Michael Gurbarg, Michael R Klapal, Michael Serrano, Michelle M Parisi, Miguel Gmanzano Maldonado, Monica L Gutierrez, Monika Borkowska, Muralidhara B Gavini, PhD, Nadeem I Chaudhry, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Nerizza B Dalena, Nerizza B Guerin, Nicholas A Violand, Niketa Patel, Nikki S Ramirez, Nina Yang, Niraj R Mehta, PhD, Parul M Patel, Paul L Bellamy, Paul Mouris, Peter R Lenahan, Prabhu P Raju, Raymond L Cheung, Regina T Brown, Remache, Richard D Manney, Richard E Needham, Richard H Penta, Robert D Tollefsen, Robert G Ruff, Robert J Maffei, Robert Sharpnack, Robin P Mathew, Rochelle K Kimmel, Rochelle L Cross, Russell J Glapion, Sachinkumar V Patel, Samir C Gala, Samuel T Walker, Sandra Kershaw, Sarah Adella Fave, Sarah Forney, Sayyem H Akbar, Sean G Casey, Shahla Parvizi, Shelby N Turner, Sherri J Liu, Shirley H Isbill, Shirley S Wen, Sidney B Priesmeyer, Simone E Pitts, Sinai I Davis, Stephanie T Durso, Stephen J Koniers, Stephen J Mottola, Stephenie M Ortiz, Steven S Wahl, Susan M Halsted, Susan T Hadman, Tamil Arasu, PhD, Tania E Garcia, Tania E Vizcaino, Tara G Bizjak, Tara R Gooen, Temar Q Williams, Thomas J Arista, Tonia F Bernard, Tracey L Harris, Tressa T Lewis, Tyanna N Hadley, Unnee Ranjan, Valerie C Reed, Valerie Reed, Verlinda A Narcisse, Wayne J Meyer, William J Muszynski, William R Chang, William W Dotts, Willy A Orantes, Xiaohan Cai, PhD, Yumi J Hiramine, Yvesna C Blaise, Yvins Dezan, Yvonne C Mcknight, Zakaria I Ganiyu

Kelli F Dobilas's Documents

Publish Date Document Type Title
July, 2001 FDA 483 Welch, Holme & Clark Co.,Inc. - Form 483, 2001-07-30
July, 2001 EIR Welch, Holme & Clark Co.,Inc. - EIR, 2001-07-30
April, 2003 FDA 483 Teva Pharmaceuticals USA, Inc. - Form 483, 2003-04-08
December, 2003 EIR Qualtech Laboratories, Inc. - EIR, 2003-12-15
November, 2003 FDA 483 Response Tri-Med Laboratories Inc - Form 483R, 2003-11-26
August, 2006 FDA 483 Bayer HealthCare LLC - Form 483, 2006-08-22
November, 2002 EIR Pharmaceutical Formulations Inc. - EIR, 2002-11-21
September, 2003 FDA 483 Response Hoffmann La Roche Inc - Form 483R, 2003-09-30
September, 2003 EIR Hoffmann La Roche Inc - EIR, 2003-09-10
June, 2002 EIR Medpointe Healthcare, Inc. - EIR, 2002-06-06
November, 2002 FDA 483 LTS Lohmann Therapy Systems Corp. - Form 483, 2002-11-07
September, 2003 FDA 483 Hoffmann La Roche Inc - Form 483, 2003-09-10
August, 2001 EIR Actavis Elizabeth LLC - EIR, 2001-08-17
June, 2005 FDA 483 Hikma Pharmaceuticals USA, Inc. - Form 483, 2005-07-13
November, 2007 FDA 483 Contract Coating Inc. - Form 483, 2007-11-06
September, 2001 FDA 483 Response CFH Laboratories LP - Form 483R, 2001-12-14
August, 2003 FDA 483 Response BASF Corporation - Form 483R, 2003-09-11
November, 2002 FDA 483 Response LTS Lohmann Therapy Systems Corp. - Form 483R, 2002-12-09
May, 2001 EIR Fisher Scientific Co., LLC - EIR, 2001-05-25
April, 2003 FDA 483 Response Teva Pharmaceuticals USA, Inc. - Form 483R, 2003-04-17
November, 2002 EIR LTS Lohmann Therapy Systems Corp. - EIR, 2002-11-07
June, 2004 EIR Hikma Pharmaceuticals USA, Inc. - EIR, 2004-06-21
November, 2006 FDA 483 Promeko, Inc. - Form 483, 2006-11-20
May, 2001 FDA 483 Fisher Scientific Co., LLC - Form 483, 2001-05-25
June, 2005 EIR Hikma Pharmaceuticals USA, Inc. - EIR, 2005-06-30
September, 2001 EIR CFH Laboratories LP - EIR, 2001-09-27
April, 2004 FDA 483 Guardian Drug Company - Form 483, 2004-04-23
October, 2002 FDA 483 P.E.L. Associates Inc - Form 483, 2002-10-31
August, 2003 FDA 483 BASF Corporation - Form 483, 2003-08-13
June, 2003 FDA 483 Organon USA Inc. - Form 483, 2003-06-27
May, 2001 FDA 483 Pharmaceutical Formulations Inc. - Form 483, 2001-05-10
October, 2009 FDA 483 LEADING PHARMA, LLC - Form 483, 2009-10-08
May, 2001 EIR Pharmaceutical Formulations Inc. - EIR, 2001-05-10
March, 2006 FDA 483 Actavis Elizabeth LLC - Form 483, 2006-03-06
August, 2003 EIR BASF Corporation - EIR, 2003-08-13
June, 2002 FDA 483 Response Medpointe Healthcare, Inc. - Form 483R, 2002-06-25
July, 2001 EIR Aphena Pharma Solutions - EIR, 2001-07-12
July, 2008 FDA 483 GlaxoSmithKline Consumer Healthcare, LP - Form 483, 2008-07-11
June, 2002 FDA 483 Medpointe Healthcare, Inc. - Form 483, 2002-06-06
September, 2003 FDA 483 Stepan Company - Form 483, 2003-09-26
September, 2002 FDA 483 Merck Sharp & Dohme LLC - Form 483, 2002-09-27
November, 2003 EIR Tri-Med Laboratories Inc - EIR, 2003-11-10
August, 2002 FDA 483 P.E.L. Associates Inc - Form 483, 2002-08-02
November, 2001 EIR CorePharma, LLC - EIR, 2001-11-16
April, 2003 EIR Teva Pharmaceuticals USA, Inc. - EIR, 2003-04-08
June, 2008 FDA 483 Rutherford Chemicals, LLC - Form 483, 2008-06-12
April, 2008 FDA 483 DAVA Pharmaceuticals, Inc. - Form 483, 2008-04-18
September, 2002 EIR Merck Sharp & Dohme LLC - EIR, 2002-09-27
September, 2008 FDA 483 Unigene Laboratories, Inc. - Form 483, 2008-09-19
November, 2002 FDA 483 Pharmaceutical Formulations Inc. - Form 483, 2002-11-21
December, 2003 FDA 483 Qualtech Laboratories, Inc. - Form 483, 2003-12-16
April, 2003 FDA 483 Response TEVA Phamaceuticals USA, Inc. - Form 483R, 2003-04-17
March, 2008 FDA 483 EMSL Analytical, Inc. DBA MPL Laboratories - Form 483, 2008-03-10
November, 2003 FDA 483 Tri-Med Laboratories Inc - Form 483, 2003-11-10
November, 2002 FDA 483 Response Pharmaceutical Formulations Inc. - Form 483R, 2002-12-11
June, 2005 FDA 483 Response Hikma Pharmaceuticals USA, Inc. - Form 483R, 2005-07-01
June, 2003 FDA 483 Response Organon USA Inc. - Form 483R, 2003-06-27
July, 2006 FDA 483 The P.F. Laboratories Inc. - Form 483, 2006-07-18
January, 2007 FDA 483 Actavis Elizabeth LLC - Form 483, 2007-01-29
April, 2003 EIR TEVA Phamaceuticals USA, Inc. - EIR, 2003-04-08
September, 2002 FDA 483 Response Merck Sharp & Dohme LLC - Form 483R, 2002-10-11
September, 2001 FDA 483 CFH Laboratories LP - Form 483, 2001-09-27
May, 2001 FDA 483 Response Pharmaceutical Formulations Inc. - Form 483R, 2001-05-29
May, 2008 FDA 483 Ferring Pharmaceuticals Inc - Form 483, 2008-05-20
June, 2003 EIR Organon USA Inc. - EIR, 2003-06-27

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more